Oncotarget

Addendum:

Addendum: A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial

PDF  |  How to cite

Oncotarget. 2022; 13:983-983. https://doi.org/10.18632/oncotarget.28263

Metrics: PDF 32 views  |   ?  

Guillermo de Velasco1, Lucia Carril-Ajuria1, Felix Guerrero-Ramos2, Teresa Alonso-Gordoa3, Juan F. Rodríguez-Moreno4, Alberto Carretero1, Maricruz Martin-Soberon1, Federico de la Rosa-Kehrmann2 and Daniel Castellano1

1Medical Oncology Department, Hospital Universitario 12 de Octubre, Comunidad de Madrid, Madrid, Spain
2Urology Department, Hospital Universitario 12 de Octubre, Comunidad de Madrid, Madrid, Spain
3Medical Oncology Department, Hospital Universitario Ramón y Cajal, Comunidad de Madrid, Madrid, Spain
4Medical Oncology Department, Hospital Universitario HM Sanchinarro, Comunidad de Madrid, Madrid, Spain

Published: August 04, 2022

Copyright: © 2022 de Velasco et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Consent was added to this article: All patients signed informed consent.

Original article: Oncotarget. 2020; 11:4457–4462. DOI: https://doi.org/10.18632/oncotarget.27807


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 28263